Arlington Partners’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-1,445
| Closed | -$110K | – | 119 |
|
|
2023
Q4 | $110K | Buy |
1,445
+1,208
| +510% | +$92.1K | 0.03% | 101 |
|
|
2023
Q3 | $16.4K | Sell |
237
-362
| -60% | -$25.1K | 0.01% | 198 |
|
|
2023
Q2 | $56.5K | Buy |
599
+362
| +153% | +$34.1K | 0.01% | 293 |
|
|
2023
Q1 | $19.6K | Buy |
237
+24
| +11% | +$1.99K | ﹤0.01% | 345 |
|
|
2022
Q4 | $15.9K | Hold |
213
| – | – | ﹤0.01% | 329 |
|
|
2022
Q3 | $18K | Hold |
213
| – | – | 0.01% | 268 |
|
|
2022
Q2 | $20K | Hold |
213
| – | – | 0.01% | 325 |
|
|
2022
Q1 | $25K | Sell |
213
-51
| -19% | -$5.99K | 0.01% | 310 |
|
|
2021
Q4 | $34K | Buy |
+264
| New | +$34K | 0.01% | 317 |
|
|
2020
Q2 | – | Sell |
-6
| Closed | – | – | 208 |
|
|
2020
Q1 | $0 | Buy |
+6
| New | – | ﹤0.01% | 326 |
|